The three sets of symptoms associated with schizophrenia—positive, negative, and
cognitive—are burdensome and have serious effects on public health, which affects up to …

To assess the effect of aerobic exercise (AZ) on global cognition and different cognition
domains in patients with schizophrenia (SZ) in daily care. Selection of the literature was …

Antipsychotic polypharmacy/drug combination treatment (APP) is a remarkably common
practice in the schizophrenia context, given the lack of general support in treatment …

The GPR139 receptor is an orphan G-protein-coupled receptor (GPCR) mainly found in the
central nervous system and is a potential therapeutic target for the treatment of …

Introduction Treatment resistant schizophrenia (TRS), the lack of response to at least two
antipsychotics administered at adequate dose and duration, epitomizes in psychiatry one of …

The integration of pharmacotherapy with psychosocial interventions has an important role to
play in the improvement of functional outcome of subjects with schizophrenia (SCZ), in all …

Striatal dysfunction has been implicated in the pathophysiology of schizophrenia, a disorder
characterized by positive symptoms such as hallucinations and delusions. Haloperidol is a …

Clozapine is the gold standard for treating treatment-resistant schizophrenia although
continuously underutilized. Previous surveys of clinicians have found that some of the most …

Introduction The severity of positive symptoms in schizophrenia is associated with poor
prognosis. About one-third of schizophrenia patients partially respond to treatment with …

Genomic prediction of antipsychotic dose and polypharmacy has been difficult, mainly due
to limited access to large cohorts with genetic and drug prescription data. In this proof of …